No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
420 (estimated)
Sponsor
Duke University · Other
Who this trial is looking for
This trial is looking for adults with type 2 diabetes who have been diagnosed with chronic kidney disease. Participants will receive improved care and management for their kidney health through this program.
Are You a Good Fit for This Trial?
You may be able to join if
I have type 2 diabetes
I have had a visit with my primary care provider within the last 24 months
I have evidence of chronic kidney disease based on lab tests done in the last 2 years
I am not receiving full guideline-recommended treatment for kidney disease
You may not be able to join if
I have type 1 diabetes
My most recent kidney function test shows eGFR below 20
I have had a kidney transplant
I have autosomal dominant polycystic kidney disease
I am currently pregnant or planning to get pregnant within a year
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* (CKD Management)
* Adults with type 2 diabetes (T2D)
* Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
* Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening…
Inclusion Criteria:
* (CKD Management)
* Adults with type 2 diabetes (T2D)
* Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
* Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):
* UACR \>300 mg/g or
* eGFR \<45 ml/min/1.73 m2 or
* UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2
* Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).
Exclusion Criteria:
* (CKD Management)
* Type 1 diabetes
* Most recent eGFR \<20 ml/min/1.73 m2
* Prior kidney transplant
* Autosomal dominant polycystic kidney disease (ADPKD)
* Active pregnancy or plans for conception within 1 year
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
